Predict your next investment

Corporation
HEALTHCARE | Biotechnology
meiragtx.com

See what CB Insights has to offer

Founded Year

2015

Stage

PIPE | IPO

Market Cap

0.61B

Stock Price

13.00

About MeiraGTx

MeiraGTx (NASDAQ:MGTX) is committed to the development of gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company focuses on the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). MeiraGTx is developing gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. Its gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.

MeiraGTx Headquarter Location

450 E 29th St 10th Floor

New York, New York, 10016,

United States

646-490-2965

Latest MeiraGTx News

MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRP

Sep 9, 2021

MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal function assessed 12 months following treatment with AAV5-RPGR is compared with retinal function in these same subjects up to 48 months prior to treatment. These data were presented today in an oral session at the EURETINA 2021 Virtual Meeting. Details of the presentation are listed below. Title: AAV5-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa Reverses Natural Disease Progression Abstract: 8412 Date and Time: Thursday, September 9, 8:00am CEST (2:00am ET) Session: Retinal Dystrophies FP Narration MeiraGTx and Janssen Pharmaceuticals are jointly developing AAV5-RPGR as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases. EURETINA 2021 Data Summary: Ten adult males aged 18-30 years with RPGR-associated XLRP from the natural history study MGT011 were identified as suitable for gene therapy intervention and were subsequently enrolled in the dose escalation phase of MGT009, the phase 1/2 Trial of AAV5-RPGR Gene Therapy Retinal function was assessed through 12 months post-treatment in MGT009 Changes in mean retinal sensitivity (MS) and the volumetric analysis of the central 30 degrees of the retinal field (V30), were examined up to 48 months pre-intervention (MGT011) and 12 months post-intervention (MGT009) For the intermediate dose escalation cohort (N=4), intervention with AAV5-RPGR therapy in the poorer-seeing eye altered the course of natural disease progression At 12 months post-intervention, MS and V30 in the treated eye were similar to levels observed 24 months pre-intervention, while the untreated eye showed a continued downward trajectory In November 2020, MeiraGTx announced 12-month data from the ongoing phase 1/2 MGT009 clinical trial of AAV5-RPGR, which demonstrated that statistically significant vision improvement was sustained 1 year after treatment in the dose escalation phase of the trial. MeiraGTx and Janssen are preparing to initiate the pivotal phase 3 Lumeos clinical trial of AAV5-RPGR for the treatment of patients with XLRP.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MeiraGTx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MeiraGTx is included in 5 Expert Collections, including Eye Health.

E

Eye Health

711 items

R

Rare Diseases

229 items

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

R

Regenerative Medicine

1,763 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

MeiraGTx Patents

MeiraGTx has filed 8 patents.

The 3 most popular patent topics include:

  • RNA
  • Gene expression
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/2/2016

12/3/2019

Molecular biology, RNA, Transcription factors, Gene expression, Genetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/2/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/3/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, RNA, Transcription factors, Gene expression, Genetics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

MeiraGTx Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MeiraGTx Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.